Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan;7(1):9-37.
doi: 10.1517/17425255.2011.532787.

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

Jian-Ping Zhang  1 , Anil K Malhotra
Affiliations
Review

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction

Jian-Ping Zhang et al. Expert Opin Drug Metab Toxicol. 2011 Jan.

Abstract

Importance of the field: Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers.

Areas covered in this review: This article reviews the pharmacogenetic literature from early 1990s to 2010, focusing on two aspects of drug action: pharmacokinetics and pharmacodynamics. Genetic variants in the neurotransmitter receptors including dopamine and 5-HT and metabolic pathways of drugs including CYP2D6 and COMT were discussed in association with clinical drug response and side effects.

What the reader will gain: Readers are expected to learn the up-to-date evidence in pharmacogenetic research and to gain familiarity to the issues and challenges facing the field.

Take home message: Pharmacogenetic research of antipsychotic drugs is both promising and challenging. There is consistent evidence that some genetic variants can affect clinical response and side effects. However, more studies that are designed specifically to test pharmacogenetic hypotheses are clearly needed to advance the field.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. van Os J, Kapur S. Schizophreniay. Lancet. 2009 Aug 22;374(9690):635–45. This is the latest general review of prevelance, etiology, psychopathology, diagnosis and treatment of schizophrenia. - PubMed
    1. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76. - PubMed
    1. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41. - PubMed
    1. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in neuro-psychopharmacology & biological psychiatry. 2003 Oct;27(7):1081–90. - PubMed
    1. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular psychiatry. 2005 Jan;10(1):79–104. Comprehensive review of antipsychotic drugs' mechanisms of action with a particular emphasis on receptors and molecular pathways. - PubMed

MeSH terms